Oryzon Genomics Sa

Oryzon Genomics Sa company information, Employees & Contact Information

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

Company Details

Employees
58
Founded
-
Address
Calle De Sant Ferran, 74, Cornellà De Llobregat,catalonia 08940,spain
Phone
34 93 515 13 13
Email
in****@****zon.com
Industry
Biotechnology
Website
oryzon.com
HQ
Cornellà de Llobregat, Catalonia
Looking for a particular Oryzon Genomics Sa employee's phone or email?

Oryzon Genomics Sa Questions

News

ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs - Yahoo Finance

ORYZON Strengthens Regulatory Strategy with the Appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs Yahoo Finance

European Medicines Agency: Phase 1b Study of Oral LDS1 Inhibitor for SCD Cleared to Proceed - Docwire News

European Medicines Agency: Phase 1b Study of Oral LDS1 Inhibitor for SCD Cleared to Proceed Docwire News

ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant - Yahoo Finance

ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant Yahoo Finance

ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025 - Yahoo Finance

ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025 Yahoo Finance

ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder - The Manila Times

ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder The Manila Times

ORYZON to Provide Corporate Progress Updates at Several Events in April - GlobeNewswire

ORYZON to Provide Corporate Progress Updates at Several Events in April GlobeNewswire

ORYZON to Participate in Upcoming Events in September and October - Yahoo! Finance UK

ORYZON to Participate in Upcoming Events in September and October Yahoo! Finance UK

Why Oryzon Genomics S.A. (ORN) stock signals breakout potential - Weekly Trade Report & Low Drawdown Investment Strategies - Trung tâm Dự báo KTTV quốc gia

Why Oryzon Genomics S.A. (ORN) stock signals breakout potential - Weekly Trade Report & Low Drawdown Investment Strategies Trung tâm Dự báo KTTV quốc gia

Oryzon wins FDA approval to begin SCLC treatment trial - Clinical Trials Arena

Oryzon wins FDA approval to begin SCLC treatment trial Clinical Trials Arena

Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology - ACS Publications

Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology ACS Publications

Oryzon med fails to improve borderline personality disorder, but executives see a path with new endpoints - Fierce Biotech

Oryzon med fails to improve borderline personality disorder, but executives see a path with new endpoints Fierce Biotech

Oryzon Receives FDA Feedback On Submitted Phase III Protocol For Borderline Personality Disorder - TradingView

Oryzon Receives FDA Feedback On Submitted Phase III Protocol For Borderline Personality Disorder TradingView

EMA authorises “Restore”, Oryzon Genomics' Phase Ib clinical trial on iadademstat in sickle cell anaemia (SCA) - The Corner .eu

EMA authorises “Restore”, Oryzon Genomics' Phase Ib clinical trial on iadademstat in sickle cell anaemia (SCA) The Corner .eu

We Think The Compensation For Oryzon Genomics S.A.'s (BME:ORY) CEO Looks About Right - simplywall.st

We Think The Compensation For Oryzon Genomics S.A.'s (BME:ORY) CEO Looks About Right simplywall.st

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase - GlobeNewswire

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase GlobeNewswire

Oryzon onboards first patient in Phase IIb borderline personality disorder study - Clinical Trials Arena

Oryzon onboards first patient in Phase IIb borderline personality disorder study Clinical Trials Arena

Insufficient Growth At Oryzon Genomics S.A. (BME:ORY) Hampers Share Price - simplywall.st

Insufficient Growth At Oryzon Genomics S.A. (BME:ORY) Hampers Share Price simplywall.st

Oryzon picks ORY-4001, an HDAC6 inhibitor, as potential treatment... - Charcot-Marie-Tooth News

Oryzon picks ORY-4001, an HDAC6 inhibitor, as potential treatment... Charcot-Marie-Tooth News

FDA provides feedback on Oryzon’s vafidemstat BPD trial protocol By Investing.com - Investing.com Nigeria

FDA provides feedback on Oryzon’s vafidemstat BPD trial protocol By Investing.com Investing.com Nigeria

Oryzon Recruiting MS Patients in Phase 2 Trial of ORY-2001, Readies Updates for Conferences - Multiple Sclerosis News Today

Oryzon Recruiting MS Patients in Phase 2 Trial of ORY-2001, Readies Updates for Conferences Multiple Sclerosis News Today

Oryzon shares soar on safety clinical trial approval - Diari ARA

Oryzon shares soar on safety clinical trial approval Diari ARA

Oryzon Genomics: A Year Of Data Readouts - Investing.com

Oryzon Genomics: A Year Of Data Readouts Investing.com

Oryzon Genomics SA Stock Price Today | BME: ORY Live - Investing.com

Oryzon Genomics SA Stock Price Today | BME: ORY Live Investing.com

Top Oryzon Genomics Sa Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant